News & Updates
Filter by Specialty:
Low-dose polypill: Another step forward in hypertension management?
A polypill comprising ultra-low doses of four antihypertensive drugs shows promise in reducing blood pressure (BP) levels compared with standard monotherapy, according to a small study presented at AHA 2022.
Low-dose polypill: Another step forward in hypertension management?
12 Dec 2022
Asians with MET exon 14 skipping NSCLC achieve durable response with tepotinib
The MET inhibitor tepotinib demonstrates clinically meaningful antitumour activity, with durable efficacy and manageable safety profile in Asian nonsmall cell lung cancer (NSCLC) patients with MET mutations associated with exon 14 skipping, as shown in the subset analysis of the single-arm, phase II VISION study.
Asians with MET exon 14 skipping NSCLC achieve durable response with tepotinib
12 Dec 2022
CV benefits of dapagliflozin evident regardless of baseline kidney function
The cardiovascular (CV) benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) is evident regardless of baseline kidney function, according to an analysis of the DELIVER* trial presented at Kidney Week 2022.
CV benefits of dapagliflozin evident regardless of baseline kidney function
11 Dec 2022
Edaravone confers neuroprotection in stroke patients
Edaravone appears to be safe and effective in the treatment of patients with ischaemic stroke, yielding improvements in activities of daily living and neurologic deficits in the short term, a study has found.
Edaravone confers neuroprotection in stroke patients
10 Dec 2022
Amivantamab/lazertinib combo shows promise in EGFR-mutated NSCLC
Among nonsmall cell lung cancer (NSCLC) patients with mutations spanning exons 18 to 21, combination treatment with amivantamab and lazertinib induces high rates of response, reports a study presented at the recent 2022 European Society for Medical Oncology Asia Congress (ESMO Asia 2022).